Therapy of metastatic bone pain.
Bone metastasis is a common sequella of solid malignant tumors such as prostate, breast, lung, and renal cancers, which can lead to various complications, including fractures, hypercalcemia, and bone pain, as well as reduced performance status and quality of life. A multidisciplinary approach is usually required not only to address the etiology of the pain and its complicating factors but also to treat the patient appropriately. Currently, the treatment of bone pain remains palliative at best with systemic therapy (analgesics, hormones, chemotherapy, steroids, and bisphosphonates) as well as local treatments (such as surgery, nerve blocks, and external beam radiation). However, many of these treatments are limited in their efficacy or duration and have significant side effects that seriously limit the cancer patient's quality of life. Various radiopharmaceuticals have shown good efficacy in relieving bone pain secondary to bone metastasis. This systemic form of metabolic radiotherapy is simple to administer and complements other treatment options. This has been associated with improved mobility in many patients, reduced dependence on narcotic and non-narcotic analgesics, improved performance status and quality of life, and, in some studies, improved survival. Additional radiopharmaceuticals are under investigation and appear promising. All of these agents, although comprising different physical and chemical characteristics, offer certain advantages in that they are simple to administer, are well tolerated by the patient if used appropriately, and can be used alone or in combination with the other forms of treatment.
Serafini
A N
AN
Division of Nuclear Medicine, Department of Radiology, University of Miami/Sylvester Comprehensive Cancer Center/Jackson Memorial Medical Center, Miami, Florida 33101, USA.
D000700:Analgesics / Q000627:therapeutic use; D000818:Animals; D001859:Bone Neoplasms / Q000150:complications / Q000556:secondary*; D006801:Humans; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D010146:Pain / Q000188:drug therapy / Q000209:etiology / Q000532:radiotherapy*; D010710:Phosphates / Q000627:therapeutic use; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use; D011868:Radioisotopes; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D012493:Samarium; D013324:Strontium / Q000627:therapeutic use; D013326:Strontium Radioisotopes / Q000627:therapeutic use
D000700:Analgesics; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D010710:Phosphates; D010761:Phosphorus Radioisotopes; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D013326:Strontium Radioisotopes; D012493:Samarium; C061972:samarium Sm-153 lexidronam; C025700:strontium chloride; C018279:sodium phosphate; D013324:Strontium